

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 October 2020 (29.10.2020)



(10) International Publication Number
WO 2020/215155 A1

(51) International Patent Classification:

C07D 413/10 (2006.01) A61P 35/00 (2006.01)
A61K 31/191 (2006.01) C07C 57/15 (2006.01)
A61K 31/5377 (2006.01)

(21) International Application Number:

PCT/CA2020/050535

(22) International Filing Date:

23 April 2020 (23.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/837,858 24 April 2019 (24.04.2019) US

(71) Applicant: UNIVERSITY HEALTH NETWORK

[CA/CA]; 190 Elizabeth Street, R. Fraser Elliot Building -
Room 1S-417, Toronto, Ontario M5G 2C4 (CA).

(72) Inventors: LI, Sze-wan; 509 Roselawn Avenue, Toronto,

Ontario M5N 1K2 (CA). BRAY, Mark Robert; 429 Allan
Street, Oakville, Ontario L6J 3R1 (CA).

(74) Agent: BAKER, James et al.; Gowling WLG (CANADA)
LLP, Suite 2600, 160 Elgin Street, Ottawa, Ontario K1P
1C3 (CA).

(81) Designated States (unless otherwise indicated, for every



kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CRYSTAL FORM S4 OF THE PLK4 INHIBITOR (LR,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1 H-IMIDAZOL-6- YL)-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE

FIG. 1



(57) Abstract: Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I)
The molar ratio between compound (I) and fumaric acid is 1.0:1.0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks at 6.6°, 9.8°, 16.3°, 21.1°, 28.7°, and 30.2° ± 0.2 in 2θ.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*